A medical technology company with tissue characterization technology
Dune Medical Ltd. a US-Israeli medical technology company, developed radiofrequency spectroscopy (RFS) which characterizes tissue and determines in real time as cancerous or not. Dune is currently focused on the breast cancer field. Its first commercial product MarginProbe (CE mark, PMA, FDA) is used to assess intra-operative surgical margins during breast cancer lumpectomy.
MarginProbe provides the surgeon with real time input on the existence of residual cancer at the margins in order to ensure complete removal of the cancerous tissue, consistently reducing the need for second surgeries by 50-80%. The product is currently in commercial use in 70 hospitals and to date over 16,000 procedures have been performed using MarginProbe.